Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
Phase 4
Completed
- Conditions
- GlaucomaOcular HypertensionOpen-Angle Glaucoma
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2013-09-13
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 84
- Registration Number
- NCT01464424
Safety and Efficacy of AL-53817 Nasal Spray Solution
Phase 1
Completed
- Conditions
- Nasal AllergiesAllergies
- Interventions
- Drug: AL-53817 nasal spray solutionOther: Vehicle nasal spray
- First Posted Date
- 2011-10-19
- Last Posted Date
- 2013-05-20
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 110
- Registration Number
- NCT01454505
- Locations
- 🇺🇸
Alcon Call Center for Trial Locations, Fort Worth, Texas, United States
Travoprost 3-Month Safety and Efficacy Study
Phase 3
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-10-18
- Last Posted Date
- 2013-10-18
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 1099
- Registration Number
- NCT01453855
Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%
Phase 3
Withdrawn
- Conditions
- Open Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-10-14
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT01452009
Nepafenac Compared to Placebo for Ocular Pain and Inflammation
Phase 3
Completed
- Conditions
- Cataract
- Interventions
- Drug: Nepafenac Ophthalmic Suspension, 0.1%Other: Nepafenac Vehicle Ophthalmic Solution
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 260
- Registration Number
- NCT01426854
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, Guangdong, China
A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
Phase 2
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-09-01
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 103
- Registration Number
- NCT01426867
Clinical Investigation of AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric Intraocular Lens (IOL)
Not Applicable
Completed
- Conditions
- Cataracts
- Interventions
- Device: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOLDevice: AcrySof® ReSTOR® Multifocal IOL Model SA60D3
- First Posted Date
- 2011-08-26
- Last Posted Date
- 2018-06-29
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 677
- Registration Number
- NCT01424189
Comparative Efficacy of SYSTANE® ULTRA vs Optive™ in Improving Tear Film Break-up Time
Not Applicable
Withdrawn
- Conditions
- Dry Eye
- Interventions
- Other: Systane UltraOther: Optive
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2012-02-08
- Lead Sponsor
- Alcon Research
- Registration Number
- NCT01417013
Efficacy and Tolerability of AZARGA® as Replacement Therapy in Patients on COMBIGAN® Therapy in Canada
Phase 4
Completed
- Conditions
- GlaucomaOcular HypertensionOpen-angle Glaucoma
- Interventions
- First Posted Date
- 2011-08-12
- Last Posted Date
- 2014-07-01
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 57
- Registration Number
- NCT01415401
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
Phase 3
Completed
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: Sodium Hyaluronate Ophthalmic Solution, 0.18%Other: Vehicle
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2013-07-08
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 1936
- Registration Number
- NCT01382225
© Copyright 2025. All Rights Reserved by MedPath